Pain, Chronic Clinical Trial
— Prosper-001Official title:
Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population (PROSPER)
NCT number | NCT04096391 |
Other study ID # | Prosper-001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 5, 2019 |
Est. completion date | April 11, 2022 |
Verified date | May 2022 |
Source | Evolve Restorative Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being conducted to compare intrathecal morphine using the commercially available intrathecal drug delivery systems (IDDS), and conventional medical management (CMM) in subjects with non-cancer, refractory chronic pain.
Status | Completed |
Enrollment | 73 |
Est. completion date | April 11, 2022 |
Est. primary completion date | April 11, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: 1. Subject must have signed and dated the IRB approved Informed Consent Form and HIPAA Authorization prior to any study procedures being performed 2. Subject must be willing and able to complete study requirements including diaries, questionnaires and attend all visits, in the opinion of the investigator 3. Subject must be male or female and at least 22 years of age 4. Subjects who are female are non-lactating and if of childbearing potential have a negative urine pregnancy test at screening 5. Subjects who are currently be receiving = 90 mg/day morphine per day dose (or MME), with stable dose at equivalent of systemic opioids at Screening 6. Subjects who are on a stable dose of opioids (no change in type or prescribed frequency or dose) for 30 days prior to the screening as documented in medical history; 7. Subjects who have refractory pain despite failure of regional minimally invasive treatment options, including epidurals, facets, rhizotomies, direct or indirect spinal stenosis treatments, etc. 8. Subjects who are a new candidate for chronic intrathecal drug therapy (including no prior intrathecal/epidural trial for pump infusion therapy) 9. Subjects have not been implanted with a spinal cord stimulator for pain 10. Subjects currently do not have an implanted spinal cord stimulator for pain 11. Subjects who have a diagnosis of nonmalignant, chronic intractable pain as documented in the medical history 12. Subjects who are medically stable and able to undergo surgery for implantation of the Prometra® II Infusion System 13. Subject must have completed a psychological evaluation within 6 months prior to Screening 14. Subject must complete an intrathecal trial resulting in candidacy for pump implantation during Screening Exclusion Criteria: A potential subject who has any contraindications listed in the Prometra® II labeling or any contraindications of intrathecal agents employed in the United States within the PACC, will be excluded. All subjects meeting any of the following criteria will also be excluded from this study: 1. Subjects currently have a spinal cord stimulator implanted for pain 2. Subjects previously had a spinal cord stimulator implanted for pain 3. Subjects who have psychological or other health conditions, financial, and/or legal concerns (within 3 months prior to Screening) that would interfere with the subject's ability to fulfill the requirements of the protocol as per the investigator's opinion 4. Subjects who have a history of alcohol abuse or illicit drug use within 2 years of screening 5. Subjects who have an active malignancy or has been diagnosed with cancer and has not been in remission for at least 1 year prior to Screening 6. Subjects who are female and who are pregnant, nursing or planning a pregnancy during the study or females of childbearing potential who are unable or unwilling to use a form of contraception during the study. 7. Subjects who plan to enroll or is currently enrolled in another investigational drug or investigational medical device study or has participated in an investigational drug or medical device study within 30 days prior to Screening 8. Subject has any condition or situation which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study At the Baseline Visit or prior to Randomization, a subject will be excluded from continued participation if the subject has: 9. Subjects that have a mean of the reported 12 hour "average" NPRS responses of < 6 on an eleven-point scale (0 to10) rated over the 5 days prior to the Baseline Visit (as recorded in the electronic Study Diary) in the absence of intolerable side effects as documented in the medical history 10. Subjects with a negative urine test for opioids at Baseline 11. Subjects with a positive Pregnancy test, if applicable 12. Subjects that failed the intrathecal trial during Screening |
Country | Name | City | State |
---|---|---|---|
United States | Evolve Restorative Center | Santa Rosa | California |
Lead Sponsor | Collaborator |
---|---|
Evolve Restorative Center | Advanced Infusion Solutions, Celéri Health, Inc., Flowonix Medical |
United States,
Deer TR, Hayek SM, Pope JE, Lamer TJ, Hamza M, Grider JS, Rosen SM, Narouze S, Perruchoud C, Thomson S, Russo M, Grigsby E, Doleys DM, Jacobs MS, Saulino M, Christo P, Kim P, Huntoon EM, Krames E, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy. Neuromodulation. 2017 Feb;20(2):133-154. doi: 10.1111/ner.12543. Epub 2017 Jan 2. Review. — View Citation
Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, De Andrés JA, Erdek M, Patin D, Grider JS, Doleys DM, Jacobs MS, Yaksh TL, Poree L, Wallace MS, Prager J, Rauck R, DeLeon O, Diwan S, Falowski SM, Gazelka HM, Kim P, Leong M, Levy RM, McDowell G II, McRoberts P, Naidu R, Narouze S, Perruchoud C, Rosen SM, Rosenberg WS, Saulino M, Staats P, Stearns LJ, Willis D, Krames E, Huntoon M, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation. 2017 Feb;20(2):96-132. doi: 10.1111/ner.12538. Epub 2017 Jan 2. Review. Erratum in: Neuromodulation. 2017 Jun;20(4):405-406. — View Citation
Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017 Feb;20(2):155-176. doi: 10.1111/ner.12579. Epub 2017 Jan 2. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare the change in Numeric Pain Rating Scale between the IDDS group and the CMM group | The Numeric Pain Rating Scale (NPRS) is a 0-10 numeric pain rating scale (11 point scale), where a higher scores equates to more pain.
The primary endpoint for this post-marketing study is the comparison of the NPRS between the IDDS group and the CMM group collected in the Study Diary at various time points. |
Comparisons will be done prior to baseline visit and at 3, 6, 9 and 12 month visits. | |
Secondary | Compare the change in PROMIS 29 scores between the IDDS group and CMM group | Compare the subject reported Patient-Reported Outcomes Measurement Information System (PROMIS) 29 between the IDDS group and CMM group. PROMIS 29 assesses pain intensity using a 0-10 numeric rating scale (11 point scale), where a higher score equates to more pain. Other health domains are scored using a Likert scale, where higher scores represent more of the specific domain being measured. The other health domains that are scored are: depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; and ability to participate in social roles and activities. | Individual subject scores recorded at baseline visit and at 3, 6, 9 and 12 month visits. | |
Secondary | Comparison of the accrued cost of therapy for pain | Compare the accrued cost of therapy for pain control including those related to adverse events, ED visits, cost of medications between the IDDS group and CMM group. | Cost of therapy will be obtained at 3, 6, 9 and 12 month visits. | |
Secondary | Comparison of other concurrent treatments | Compare the number of other concurrent treatments performed on each subject between the IDDS group and CMM group. | Individual subject counts recorded at 3, 6, 9 and 12 month visits will be compared. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Recruiting |
NCT05037682 -
Pain and Opioid Management in Older Adults
|
N/A | |
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Recruiting |
NCT05382962 -
iCanCope With Post-Operative Pain (iCanCope PostOp)
|
N/A | |
Recruiting |
NCT04285112 -
SPRINT: Signature for Pain Recovery IN Teens
|
||
Active, not recruiting |
NCT04850079 -
EHR Precision Drug Treatment in Neonates
|
||
Completed |
NCT03272139 -
Interscalene Block Versus Superior Trunk Block
|
Phase 4 | |
Completed |
NCT03271151 -
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT03886142 -
Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis
|
N/A | |
Recruiting |
NCT05761392 -
APP-based Precise Management System of Chronic Intractable Pain
|
N/A | |
Recruiting |
NCT05877157 -
Pain AND Opioids After Surgery
|
||
Completed |
NCT03947749 -
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
|
||
Completed |
NCT03280017 -
Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain
|
Phase 4 | |
Recruiting |
NCT04874038 -
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
|
Phase 3 | |
Completed |
NCT04280796 -
Changes in Affective Pain Processing in Human Volunteers
|
N/A | |
Withdrawn |
NCT05125978 -
Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
|
Phase 2 | |
Not yet recruiting |
NCT04328805 -
Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome.
|
Phase 4 | |
Completed |
NCT04976738 -
A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
|
Phase 1/Phase 2 | |
Completed |
NCT04089618 -
Meditation Based Lifestyle Modification in Chronic Pain
|
N/A | |
Recruiting |
NCT05699837 -
Alpha Entrainment for Pain and Sleep (Extension)
|
N/A |